Oak Hill Bio
PrivateLast Round
Series A
Jun 1, 2026
Total Funding Raised
$32.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Oak Hill Bio operates in Healthcare & Life Sciences and is based in Altrincham. Its latest recorded funding round was a Series A round in June 2026.
Oak Hill Bio is a biotechnology company that acquires and develops deprioritized late-stage rare disease drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oak Hill Bio Comparables
Compare Oak Hill Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 80% | |
| CourageAS Biotherapeutics | 77% | |
| MavriX Bio | 74% |
For institutional investors. Book with your work email.
Oak Hill Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 1, 2026 | ||||
| Seed | Feb 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oak Hill Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| venBio | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 57% MoM.
- Jun 1, 2026
$33M round led by Balyasny Asset Management, Janus Henderson, and venBio.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 6, 2026
Oak Hill Bio Ltd has hired Joerg Hipp as Chief Translational Science Officer; he joins from Roche with more than 15 years of neuroscience experience to support the pivotal clinical development of rugonersen.
- hiresOct 6, 2026
Oak Hill Bio Ltd appoints Joerg Hipp, PhD as Chief Translational Science Officer to support the translational development of rugonersen for Angelman syndrome in Massachusetts on Oct 6th '26.
- is_developingSep 3, 2026
Oak Hill Bio Ltd is developing Angelman therapies that work in a similar way to those from Ionis Pharmaceuticals.
For institutional investors. Book with your work email.
Oak Hill Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oak Hill Bio's valuation, stock price, and market status.
Is Oak Hill Bio a public or private company?
Oak Hill Bio is a private company.
What is the current stock price of Oak Hill Bio?
Oak Hill Bio is a private company, so its shares have no public market price. Caplight tracks Oak Hill Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oak Hill Bio worth (valuation)?
Valuation information for Oak Hill Bio is not publicly available.
Can I buy Oak Hill Bio stock?
Oak Hill Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oak Hill Bio's last funding round?
Oak Hill Bio's most recent funding round was Series A on June 1, 2026.
Who are the main investors in Oak Hill Bio?
Key investors in Oak Hill Bio include Janus Henderson Group, Balyasny Asset Management L.P., venBio.
Will Oak Hill Bio IPO soon?
No public IPO plans have been announced for Oak Hill Bio.
How can I track Oak Hill Bio secondary market activity?
Caplight tracks bids, offers, and trades in Oak Hill Bio's shares on secondary markets.